Results 31 to 40 of about 8,864 (209)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates

EJNMMI Physics, 2021
Background Kidney dosimetry after peptide receptor radionuclide therapy using 177Lu-labelled somatostatin analogues is a procedure with multiple steps.
Peter Frøhlich Staanum, Anders Floor Frellsen, Marie Louise Olesen, Peter Iversen, Anne Kirstine Arveschoug   +4 more
doaj   +1 more source

Repurposed Effect of 177Lu-DOTATATE in the Treatment of Mantle Cell Lymphoma

, 2022
Mantle cell lymphoma (MCL) is an uncommon subcategory of non-Hodgkin lymphoma (NHL). Pathogenesis primarily includes overexpression of CCND1 and SOX11 along with other molecular aberrations. Lutetium 177Lu-DOTATATE is a radiolabeled somatostatin analogue
Michael Schwartz, Gerard Chaaya, Elajami, Mohamad K., Burton, Lorena P., Lorena P. Burton, Bahmad, Hisham F., Chaaya, Gerard, Hisham F. Bahmad, Mohamad K. Elajami, Schwartz, Michael   +9 more
core   +1 more source

Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial)

Trials, 2020
Background Lutetium-177-DOTA-octreotate (177Lu-DOTATATE) significantly increases survival and response rates in patients with grade I and grade II neuroendocrine tumors (NETs). However, survival and response rates are significantly lower in patients with
Sander C. Ebbers, Arthur J. A. T. Braat, Adriaan Moelker, Marcel P. M. Stokkel, Marnix G. E. H. Lam, Maarten W. Barentsz   +5 more
doaj   +1 more source

Targeted alpha-particle therapy in neuroendocrine neoplasms: A systematic review

World Journal of Nuclear Medicine, 2021
Neuroendocrine neoplasms (NENs) are a very diverse group of tumors with a worldwide rise in incidence. Systemic therapy remains the mainstay treatment for unresectable and/or metastatic NENs.
Thuan Koh, Eva Bezak, David Chan, Gabrielle Cehic   +3 more
doaj   +1 more source

Radionuclide generator-based production of therapeutic 177Lu from its long-lived isomer 177mLu

EJNMMI Radiopharmacy and Chemistry, 2019
Background In this work, a lutetium-177 (177Lu) production method based on the separation of nuclear isomers, 177mLu & 177Lu, is reported. The 177mLu-177Lu separation is performed by combining the use of DOTA & DOTA-labelled peptide (DOTATATE) and liquid-
Rupali Bhardwaj, Hubert Th. Wolterbeek, Antonia G. Denkova, Pablo Serra-Crespo   +3 more
doaj   +1 more source

P09.05 177Lu-DOTATATE therapy in progressive meningioma

Neuro-Oncology, 2019
Abstract BACKGROUND Progressive meningioma is a challenging condition with a decreasing number of treatment options over the course of disease. Neurovascular involvement and multifocal disease often complicate surgical management. In addition, repeated radiotherapy carriers a risk of side effects.
M Müther, W Roll, B Zinnhardt, M Schäfers, K Rahbar, B Brokinkel, W Stummer   +6 more
openaire   +2 more sources

177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient with Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation

, 2019
We presented a promising result of radionuclide therapy using 177Lu-PSMA and 177Lu-DOTATATE in a patient with prostatic adenocarcinoma and neuroendocrine differentiation. Functional imaging of somatostatin receptors in patients with metastatic castration-
Elahe Pirayesh, Iraj Nabipour, Amini,, A, Hojjat Ahmadzadehfar, Esmaili,, A, Zohrabi,, F, Pirayesh,, E, Farshad Zohrabi, Jafari,, E, Nabipour,, I, Abdolhamid Esmaili, Rekabpour,, S.J, Esmail Jafari, Abdullatif Amini, Seyed Javad Rekabpour, Ahmadzadehfar,, H, Majid Assadi, Assadi,, M   +17 more
core   +1 more source

Case Report: Hypoglycemia Due to Metastatic Insulinoma in Insulin-Dependent Type 2 Diabetes Successfully Treated With 177 Lu-DOTATATE

Frontiers in Endocrinology, 2022
We describe a 96-year-old man with insulin-dependent type 2 diabetes mellitus who, despite insulin cessation, presented with recurrent hypoglycemia associated with confirmed inappropriate endogenous hyperinsulinemia.
Shejil Kumar, Mariah Melek, Peter Rohl
doaj   +1 more source

Investigating intrinsic radiosensitivity biomarkers to peptide receptor radionuclide therapy with [177Lu]Lu-DOTATATE in a panel of cancer cell lines

, 2021
Introduction: [177Lu]Lu-DOTATATE is an effective systemic targeted radionuclide therapy for somatostatin receptor (SSTR) positive metastatic or inoperable neuroendocrine tumours (NET). However, for a given injected activity, tumour responses are variable.
Delbart, Wendy, Ghanem, Ghanem Elias, Flamen, Patrick, Karfis, Ioannis, Wimana, Zéna   +4 more
core   +1 more source

Recombinant α1-Microglobulin (rA1M) Protects against Hematopoietic and Renal Toxicity, Alone and in Combination with Amino Acids, in a 177Lu-DOTATATE Mouse Radiation Model

, 2023
177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) is used clinically to treat metastasized or unresectable neuroendocrine tumors (NETs). Although 177Lu-DOTATATE is mostly well tolerated in patients, bone marrow suppression and long-term renal ...
Suvi Vallius, Flygare, Johan, Kristiansson, Amanda, Eva Forssell-Aronsson, Jonas Ahlstedt, Ahlstedt, Jonas, Vallius, S., Ahlstedt, J., Johan Flygare, Åkerström, Bo, Abdul Ghani Alattar, Gram, Magnus, Alattar, Abdul Ghani, Karlsson, Helena, Forssell-Aronsson, Eva,, Strand, S. E., Alattar, A. G., Akerstrom, B., Flygare, J., Sven-Erik Strand, Strand, Sven-Erik, Karlsson, H., Bo Åkerström, Amanda Kristiansson, Vallius, Suvi, Helena Karlsson, Forssell-Aronsson, Eva, Gram, M., Magnus Gram, Kristiansson, A.   +29 more
core   +2 more sources